ARID1A and the gene 'switches' that shape pulmonary arterial hypertension
Official title: The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension
Funded at Icahn School of Medicine at Mount Sinai · NIH-11289363 · Data updated 2026-11-12
This project looks at whether changes in the ARID1A gene and related epigenetic switches drive the blood-vessel scarring that causes pulmonary arterial hypertension.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 5, 2024 |
| Project end | February 28, 2028 |
| Funding year | 2026 |
| Award (this year) | $824,916 |
| NIH project number | 5R01HL173203-03 |
| Project ID | NIH-11289363 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with pulmonary arterial hypertension who are willing to provide clinical information or tissue/blood samples, and who can travel to or work with the study site, would be ideal candidates for any human sampling activities.
✕Less likely to help
People without PAH, those with other forms of pulmonary hypertension, or patients seeking immediate therapeutic benefit should not expect direct personal benefit from this laboratory-focused project.
What this research studies
From a patient's perspective, researchers will examine how the ARID1A protein and other epigenetic regulators change the way genes are turned on or off in lungs affected by PAH. They will use lab models, including cells and animal models, and modern genomic tools (like ATAC-seq) to map chromatin accessibility and gene activity in diseased pulmonary vessels. The team will probe how ARID1A interacts with the enzyme EZH2 and how imbalances may promote vascular remodeling and cell survival. Results aim to point to molecular pathways that could be targeted to slow or reverse vessel scarring.
Why it matters
Potential benefit: If successful, this work could identify new molecular targets to develop treatments that prevent or reverse the blood-vessel remodeling that causes PAH.
How similar studies have gone: ARID1A-related research has revealed important roles in cancer and cell regulation, but applying ARID1A and chromatin-mapping approaches specifically to PAH is largely novel.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.